“…And the main strategies include: (1) conducting the metabonomic and proteomic research (Shi et al, 2014b ; Zou et al, 2014 ; Jiang et al, 2015 ; Sun et al, 2015 ); (2) constructing MiRNA-target network (Liao et al, 2016 ; Liu et al, 2017 ); (3) integrating the classical formulas or herb pair (Chen et al, 2016 ; Xu et al, 2016 ; Zhou et al, 2016 ; Yue et al, 2017 ); (4) analyzing compound–nature pairs from TCM via chemical space visualizations (Liang et al, 2013 ; Fu et al, 2017 ); (5) using compound-target-disease associations to reconstruct the biologically-meaningful networks based on systems pharmacology (Zhou and Wang, 2014 ). Moreover, in recent years, a growing number of studies have focused on the biological mechanisms underlying BS with IHD (Mao et al, 2004 ; Liu Y. et al, 2011 ; Chen, 2012 ; Hao et al, 2013 ; Huang et al, 2013 ; Su et al, 2013 ; Wang and Yu, 2013 ; Li et al, 2015 ), PS with IHD (Wang et al, 2009 ; Zhao, 2009 ; Fang et al, 2011 ; Kong et al, 2014 ) and PSCS with IHD (Zhang et al, 1995 , 1999 ; Liu et al, 2008 ; Bai and Song, 2012 ; Lin et al, 2014 ; Zhao L. et al, 2014 ; Ren et al, 2015 ). However, the molecular mechanisms of PSCS with IHD have not been fully elucidated clearly and have not yet been investigated from a network medicine perspective (Hopkins, 2007 ; Li and Zhang, 2013 ), in particular the symptoms or cluster of symptoms (corresponding to specific syndromes) have been always ignored to be explored in system biology (Zhou et al, 2014a , b ), although symptoms were the most common and focused phenotypes in TCM (Chung, 2014 ).…”